Cue Biopharma (CUE) to Release Earnings on Wednesday

Key Points

• Cue Biopharma is set to report its Q2 2025 earnings on August 13th, with analysts predicting a loss of ($0.13) per share and revenue of $2.00 million.
• In its previous quarter, Cue Biopharma reported a loss of ($0.17) per share and revenues of $0.42 million, falling short of estimates.
• The stock has recently seen a 10% increase, currently trading at $0.84, with a market cap of $63.15 million.

Cue Biopharma (NASDAQ:CUE - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect Cue Biopharma to post earnings of ($0.13) per share and revenue of $2.00 million for the quarter.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). Cue Biopharma had a negative net margin of 507.87% and a negative return on equity of 228.43%. The business had revenue of $0.42 million during the quarter, compared to analyst estimates of $0.90 million. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock traded up $0.02 during trading on Friday, reaching $0.83. 176,285 shares of the company's stock were exchanged, compared to its average volume of 512,087. Cue Biopharma has a 1-year low of $0.45 and a 1-year high of $1.99. The company has a market cap of $62.62 million, a P/E ratio of -1.24 and a beta of 1.53. The firm's 50-day moving average price is $0.74 and its 200 day moving average price is $0.89.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.